Even as Biogen weighs strategic options for its biosimilars unit, the group is celebrating an industry first. Biogen’s version of Roche’s autoimmune drug Actemra has won FDA approval, the company said ...
The FDA has approved the first biosimilar version of the interleukin-6 (IL-6) blocker tocilizumab, to be marketed as Tofidence and with indications for rheumatoid arthritis (RA), systemic juvenile ...
BOSTON, Nov. 7 (Reuters) - Swiss drugmaker Roche Holding AG said on Wednesday that its experimental rheumatoid arthritis drug, Actemra, was effective in the second of five late-stage clinical trials.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback